W
WAVEMAN · COMPANY
CRL · Charles River Laboratories International, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
PHARMA & BIOTECH · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · CIK 0001100682
FORM 144 · 10☆ WATCH
INSIDER NET · 180D
-$42.6M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
-0.9%
XBRL, annual
NET MARGIN
-3.6%
CONVERSIONS · 180D
11
codes C/M, not in net · $15.4M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$42.6M over 180 days
-$42.6M over 90 days
below 94% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
-0.9% year over year
below 58% of Pharma & Biotech
MARGIN
-3.6% net margin
more than 62% of Pharma & Biotech
BUYBACKS
$323.9M repurchased, FY to 2026-06-27
more than 83% of Pharma & Biotech
SHORT
7.2% of shares outstanding short · 4.1 days to cover · settled 2026-07-31
more than 65% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$42.6M across 6 people in 180 days.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +81.9%
+81.9%12M
-10%+22%+54%+85%2025-092025-102025-122026-032026-052026-072026-09 2026-06-29 · FOSTER JAMES C sold $16.9M2026-08-25 · FOSTER JAMES C sold $10.1M2026-08-10 · FOSTER JAMES C sold $7.9M2026-08-11 · Girshick Birgit sold $1.8M2026-08-05 · Parisotto Shannon M sold $1.3M2026-08-06 · Creamer Victoria L sold $1.1M2026-08-11 · Parisotto Shannon M sold $1.0M2026-08-19 · Parisotto Shannon M sold $599.7K2026-08-06 · Knell Michael Gunnar sold $330.1K2026-08-06 · Knell Michael Gunnar sold $311.5K2026-08-06 · Knell Michael Gunnar sold $234.8K2026-08-06 · Knell Michael Gunnar sold $211.8K2026-08-06 · Knell Michael Gunnar sold $190.3K2026-08-06 · Knell Michael Gunnar sold $163.6K2026-08-18 · Andrews Nancy C sold $163.4K2026-08-06 · Knell Michael Gunnar sold $127.8K2026-08-06 · Knell Michael Gunnar sold $104.4K2026-08-06 · Knell Michael Gunnar sold $55.9K2026-03-03 · LaPlume Joseph W bought $4.4K2026-08-25 · FOSTER JAMES C filed to sell $10.1M2026-08-19 · Parisotto Shannon M filed to sell $599.7K2026-08-18 · Nancy C Andrews filed to sell $163.3K2026-08-11 · Girshick Birgit filed to sell $1.8M2026-08-11 · Parisotto Shannon M filed to sell $1.0M2026-08-10 · FOSTER JAMES C filed to sell $7.9M2026-08-06 · Michael Knell filed to sell $1.7M2026-08-06 · Victoria Creamer filed to sell $1.1M2026-08-05 · Parisotto Shannon M filed to sell $1.3M2026-06-29 · FOSTER JAMES C filed to sell $16.9M
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $42.6M sold by insiders over 180 days, $42.6M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, CHARLES RIVER LABORATORIES INTERNATIONAL, INC. insiders sold a net $42.6M of stock across 202 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
FOSTER JAMES C
Director
SELL
2026-08-25
33,561.0
$10.1M
Parisotto Shannon M
CEVP, Disc & Safety Assessment
SELL
2026-08-19
2,039.0
$599.7K
Andrews Nancy C
Director
SELL
2026-08-18
573.0
$163.4K
Parisotto Shannon M
CEVP, Disc & Safety Assessment
SELL
2026-08-11
3,714.0
$1.0M
Girshick Birgit
Chief Executive Officer
SELL
2026-08-11
6,500.0
$1.8M
202 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 197 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
FOSTER JAMES C
FILED 2026-08-25
$10.1M
Parisotto Shannon M
FILED 2026-08-19
$599.7K
Nancy C Andrews
FILED 2026-08-18
$163.3K
Girshick Birgit
FILED 2026-08-11
$1.8M
Parisotto Shannon M
FILED 2026-08-11
$1.0M
Government contracts
USASpending.gov · total award ceilings over the contract's life, including awards won through subsidiaries — not annual revenue
Department Of Health And Human Services
IGF::OT::IGF MANAGEMENT, OPERATION, PROFESSIONAL, AND TECHNICAL SUPPORT SERVICES FOR NIAID ANIMAL C · 2018-04-13
$112.0M
Department Of Health And Human Services
NATIONAL INSTITUTES OF HEALTH (NIH), NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) · 2026-03-01
$5.3M
FEDERAL AWARDS ≥ $25M IN THE LAST 90 DAYS · MATCHED VIA SAM.GOV PARENT REGISTRY
Corporate PAC
FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors
Charles River Laboratories International Inc Pac
CYCLE 2026 · $0K SPENT
-
FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION
Executive pay vs shareholder return · Ms. Pease
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2023
$14.1M
$18.9M
$3.7M
+56%
+43%
2022
$13.4M
-$11.5M
$3.3M
+43%
+40%
2021
$13.7M
$43.2M
$4.4M
+143%
+41%
2020
$13.5M
$50.0M
$2.8M
+66%
+11%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$4.0B$4.0B$4.1B$4.0B
OPERATING INCOME$25.2M$227.3M$617.3M$651.0M
NET INCOME$-144.3M$22.2M$474.6M$486.2M
EPS (DILUTED)-2.910.209.229.48
OPERATING CASH FLOW$737.6M$734.6M$683.9M$619.6M
CASH$213.8M$194.6M$276.8M$233.9M
BUYBACKS$360.7M$119.2M$24.2M$38.7M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →